The Role of the Immune Response in Merkel Cell Carcinoma
AbstractMerkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer. The Merkel cell polyomavirus (MCPyV) is implicated in its pathogenesis. Immune mechanisms are also implicated. Patients who are immunosuppressed have an increased risk. There is evidence that high intratumoral T-cell counts and immune transcripts are associated with favorable survival. Spontaneous regressions implicate immune effector mechanisms. Immunogenicity is also supported by observation of autoimmune paraneoplastic syndromes. Case reports suggest that immune modulation, including reduction of immune suppression, can result in tumor regression. The relationships between MCPyV infection, the immune response, and clinical outcome, however, remain poorly understood. Circulating antibodies against MCPyV antigens are present in most individuals. MCPyV-reactive T cells have been detected in both MCC patients and control subjects. High intratumoral T-cell counts are also associated with favorable survival in MCPyV-negative MCC. That the immune system plays a central role in preventing and controlling MCC is supported by several observations. MCCs often develop, however, despite the presence of humoral and cellular immune responses. A better understanding on how MCPyV and MCC evade the immune response will be necessary to develop effective immunotherapies. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Triozzi, P.L.; Fernandez, A.P. The Role of the Immune Response in Merkel Cell Carcinoma. Cancers 2013, 5, 234-254.
Triozzi PL, Fernandez AP. The Role of the Immune Response in Merkel Cell Carcinoma. Cancers. 2013; 5(1):234-254.Chicago/Turabian Style
Triozzi, Pierre L.; Fernandez, Anthony P. 2013. "The Role of the Immune Response in Merkel Cell Carcinoma." Cancers 5, no. 1: 234-254.